Renal toxicity associated with small-molecule radionuclide ther-apy has been shown to be dose-limiting for many clinical studies. Strategies formaximizing dose to the target tissueswhile sparing normal critical organs based on absorbed dose and biologic response parameters are commonly used in external-beam therapy. However, radiopharmaceuticals passing though the kidneys result in a differential dose rate to suborgan elements, presenting a significant challenge in assessing an accurate dose–response relationship that is predictive of toxicity in future patients. We have modeled the multiregional internal dosimetry of the kidneys combined with the biologic response parameters based on experience with brachytherapy and external-beam ra-diati...
Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequen...
Dose-volume modeling of late and acute toxicity in radiotherapy for prostate cancer is a rapidly evo...
Metastatic disease requires a systemic approach to therapy. Alpha particle radiopharmaceutical thera...
The manuscripts included in this special issue of Cancer Biotherapy & Radiopharmaceuticals highl...
The development of novel, systemically administered radionuclide therapies (such as radioimmunother-...
Purpose: To model dose-response relationships for in vivo experiments with radiolabelled peptides en...
PURPOSE: Peptide receptor radionuclide therapy (PRRT) delivers high absorbed doses to kidneys and ma...
were no funding sources for this work. This paper reviews the generalized application of the linear ...
This article discusses the model of biokinetics of radiopharmaceuticals used for radionu-clide diagn...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 pati...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
International audienceAbsorbed dose heterogeneity in kidney tissues is an important issue in radioph...
Peptide receptor radionuclide therapy (PRRT), with (90)Y-DOTATOC and (177)Lu-DOTATATE as most clinic...
Peptide receptor radionuclide therapy (PRRT), with (90)Y-DOTATOC and (177)Lu-DOTATATE as most clinic...
Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequen...
Dose-volume modeling of late and acute toxicity in radiotherapy for prostate cancer is a rapidly evo...
Metastatic disease requires a systemic approach to therapy. Alpha particle radiopharmaceutical thera...
The manuscripts included in this special issue of Cancer Biotherapy & Radiopharmaceuticals highl...
The development of novel, systemically administered radionuclide therapies (such as radioimmunother-...
Purpose: To model dose-response relationships for in vivo experiments with radiolabelled peptides en...
PURPOSE: Peptide receptor radionuclide therapy (PRRT) delivers high absorbed doses to kidneys and ma...
were no funding sources for this work. This paper reviews the generalized application of the linear ...
This article discusses the model of biokinetics of radiopharmaceuticals used for radionu-clide diagn...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 pati...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
International audienceAbsorbed dose heterogeneity in kidney tissues is an important issue in radioph...
Peptide receptor radionuclide therapy (PRRT), with (90)Y-DOTATOC and (177)Lu-DOTATATE as most clinic...
Peptide receptor radionuclide therapy (PRRT), with (90)Y-DOTATOC and (177)Lu-DOTATATE as most clinic...
Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequen...
Dose-volume modeling of late and acute toxicity in radiotherapy for prostate cancer is a rapidly evo...
Metastatic disease requires a systemic approach to therapy. Alpha particle radiopharmaceutical thera...